A group of researchers from Yale recently came up with a new drug therapy for patients suffering from chronic heart failure. It also serves to improve markers of poor prognosis in people hospitalized with worst cases of heart failure. The latest findings show that the drug has the ability to improve outcomes for those who are acutely ill with heart conditions. Thus it can revolutionize the treatment of heart diseases.
A research study has been published recently in the publication called the New England Journal of Medicine. It was presented.
When the human heart cannot pump blood efficiently, it can lead to acute heart failure. This is the main cause of hospitalizations in the elderly. Not just that, they need to be re-hospitalized and it can even cause death.
But the care procedure for such a life threatening condition has remained the same. It is mainly comprised of medications and diuretics that held to better the flow of blood.
To check if a drug named sacubitril-valsartan, which has been approved by the FDA, can improve the condition of people suffering from acute heart failure, the research team carried out a double-blind clinical trial named PIONEER-HF.
Over 800 people afflicted with heart failure in around 129 cities were administered either the standard therapy comprising of enalapril or sacubitril-valsartan. During the eight weeks of trial duration, researchers kept a tab on the blood pressure, functioning of the kidneys, and others key parameters. At the end it was found that patients administered with sacubitril-valsartan showed swift reduction in NT-proBNP.
